Cookie policy: This site uses cookies (small files stored on your computer) to simplify and improve your experience of this website. Cookies are small text files stored on the device you are using to access this website. For more information please take a look at our terms and conditions. Some parts of the site may not work properly if you choose not to accept cookies.


Subscribe or Register

Existing user? Login


T-cell therapies for cancer: from outsider to pharmaceutical darling

Citation: The Pharmaceutical Journal DOI: 10.1211/PJ.2016.20201573

Have your say

For commenting, please login or register as a user and agree to our Community Guidelines. You will be re-directed back to this page where you will have the ability to comment.

Recommended from Pharmaceutical Press

Search an extensive range of the world’s most trusted resources

Powered by MedicinesComplete
  • Print
  • Share
  • Comment
  • Save
  • Print Friendly Version of this pagePrint Get a PDF version of this webpagePDF

Supplementary images

  • Micrograph of a group of tumor-specific T cells attacking a tumor cell
  • Graphic showing chimeric antigen receptor (CAR) therapy and T cell receptor therapy
  • Christopher Klebanoff, a staff clinician in the experimental transplantation and immunology branch of the National Cancer Institute (NCI)
  • Renier Brentjens, director of cellular therapeutics at Memorial Sloan Kettering
  • Robert Hershberg, chief scientific officer at New Jersey-based biotechnology company Celgene

Jobs you might like

Newsletter Sign-up

Want to keep up with the latest news, comment and CPD articles in pharmacy and science? Subscribe to our free alerts.